Navigation Links
Jennerex to Present Final Survival Data From Randomized Phase 2 Clinical Trial of JX-594 in Advanced Liver Cancer at American Association for the Study of Liver Diseases Annual Meeting
Date:11/2/2011

SAN FRANCISCO, Nov. 2, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that final data from its Phase 2 randomized clinical trial in advanced liver cancer patients will be presented on Monday, November 7, 2011 at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place November 4-8, 2011 in San Francisco, California.  These data, evaluating multi-dose administration of JX-594 in U.S., Korean and Canadian patients with advanced liver cancer, were selected for an oral presentation in the late-breaking oral session of the conference.

The presentation details are as follows:

Abstract Title: "A Randomized, Controlled Phase 2 Clinical Trial of JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, in Patients with Advanced Hepatocellular Carcinoma: Final Data." (Abstract #LB1)
Presenter: Tony Reid, M.D., Ph.D., professor of medicine, hematology/oncology, director of clinical investigation, and the tumor growth, invasion and metastasis program, Moores UCSD Cancer Center at the University of California, San Diego
Session: Late-Breaking Oral Session, November 7, 2011, 2:45 p.m. PT

JX-594: A Multi-Mechanistic Approach To Targeting Cancer

JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the shutdown of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into
'/>"/>

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jennerex Publishes Clinical Data in Journal, Nature, Demonstrating Intravenous Delivery of Multi-Mechanistic Cancer-Targeted Oncolytic Poxvirus JX-594 to Tumors
2. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
3. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
4. Jennerex to Present JX-594 Liver Cancer Clinical Data at American Society of Gene and Cell Therapy Meeting
5. Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
6. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
7. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
8. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
9. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
10. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
11. Jennerex Closes $5 Million First Tranche of Series C Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Fertility Associates of Memphis has announced a new ... network of more than 20 contributing fertility practices ... access to a national pool of frozen donor ... of Memphis is the only fertility clinic in the ... Dr. William Kutteh , director of Fertility Associates of ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of the ... Maroulis, Pharm.D. to the newly created position of Vice ... position, Dr. Maroulis will continue to manage the entire ... multi-site pharmacies as the company expands. Dr. Maroulis has ... he has served in many different capacities in the ...
(Date:12/19/2014)... , Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... today that they have been acquired by Roche (SIX: ... a privately held company that provides a big data ... sequencing (NGS) data for the academic and translational research ... Unit, and will continue to focus on development of ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy ... has an expanded team of Regional Pharmaceutical Care ... prescriber offices in their regions, with specific areas ... a variety of Regional Pharmaceutical Care Liaisons specializing ... hepatitis C help prescribers understand all the new ...
Breaking Biology Technology:Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3
... 11 Pressure,BioSciences, Inc. (Nasdaq: PBIO ... it has entered into a Cooperative Research ... Army Medical Research Institute of,Infectious Diseases (USAMRIID). ... use of the Company,s patented pressure cycling ...
... and safety of food supply, as well as increasing concerns ... to experience spiraling growth given the recent success of commercialized ... pipeline. , ... San Jose, California ...
... Update on Key Regulatory Milestones, SEATTLE, Sept. 11 ... MTA: CTIC) announced today that it will host an,investor ... investor day will,provide an update from executive management on ... meeting will be an,invitation-only event. A webcast and live ...
Cached Biology Technology:Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID) 2Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID) 3Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID) 4Pressure BioSciences, Inc. Announces Research Agreement With the US Army Medical Research Institute of Infectious Diseases (USAMRIID) 5Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 2Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 3Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 4
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
(Date:12/10/2014)... -- You,ve been here before: you desperately need to sign ... site key or the answer to your secret question. What,s ... Today, Hoyos Labs , a digital infrastructure ... put an end to the frustration that comes with usernames, ... leverages a user,s smartphone to acquire his or her biometrics ...
(Date:12/10/2014)... , Dec. 9, 2014  Wake Forest Baptist Medical Center ... for its School of Medicine. Funding for this $50 ... campaign that will be publicly launched next summer. ... in the former 60 series R.J. Reynolds Tobacco Company ... Construction will begin immediately with plans to be ready ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... honeybee hives arrests the growth of prostate cancer cells and ... at the University of Chicago Medicine. Caffeic acid phenethyl ... propolis, the resin used by bees to patch up holes ... natural remedy for conditions ranging from sore throats and allergies ...
... Biology Reports published today argues that recent advances ... of the global demand for liquid transportation fuels, drastically reducing ... burning fossil fuels, without having an impact on food production. ... of detrimental climate change is the emission of greenhouse gasses ...
... brain activity in the rat brain that play a ... decision-making. The discovery, which builds on the team,s previous ... post-traumatic stress syndrome. The researchers previously identified patterns ... region critical for memory storage. The patterns sometimes represented ...
Cached Biology News:Beehive extract shows potential as prostate cancer treatment 2Beehive extract shows potential as prostate cancer treatment 3Better plants for biofuels 2Rats recall past to make daily decisions 2Rats recall past to make daily decisions 3
... convenient, and efficient native protein concentration following ... spin column to make handling easy. The ... which were electro-eluted in their native condition. ... high binding capacity fo all pH values. ...
... optically clear polystyrene with frosted labeling ... for cell counting. 100% integrity tested. ... new product number, created to easily ... no availability yet, please order under ...
... The Corning CellBIND surface is produced ... a more hydrophilic surface giving more consistent, ... yields. CellBIND enhances cell attachment and growth ... serum-free medium. • CellBIND may provide a ...
... system, 100-240 V, uses xMAP technology for ... proteins and peptides in one microplate well. ... to 100 color-coded bead sets, each of ... reactant (enzyme substrates, receptors, antigens, or antibodies) ...
Biology Products: